163 related articles for article (PubMed ID: 32159800)
21. Effects of steroid pulse therapy on immunoglobulin-resistant Kawasaki disease.
Furukawa T; Kishiro M; Akimoto K; Nagata S; Shimizu T; Yamashiro Y
Arch Dis Child; 2008 Feb; 93(2):142-6. PubMed ID: 17962370
[TBL] [Abstract][Full Text] [Related]
22. Comparison of second-line therapy in IVIg-refractory Kawasaki disease: a systematic review.
Crayne CB; Mitchell C; Beukelman T
Pediatr Rheumatol Online J; 2019 Nov; 17(1):77. PubMed ID: 31775898
[TBL] [Abstract][Full Text] [Related]
23. Is aspirin necessary in the acute phase of Kawasaki disease?
Huang X; Huang P; Zhang L; Xie X; Xia S; Gong F; Yuan J; Jin L
J Paediatr Child Health; 2018 Jun; 54(6):661-664. PubMed ID: 29271519
[TBL] [Abstract][Full Text] [Related]
24. Re-treatment regimens for acute stage of Kawasaki disease patients who failed to respond to initial intravenous immunoglobulin therapy: analysis from the 17th nationwide survey.
Uehara R; Yashiro M; Oki I; Nakamura Y; Yanagawa H
Pediatr Int; 2007 Aug; 49(4):427-30. PubMed ID: 17587262
[TBL] [Abstract][Full Text] [Related]
25. Early treatment with intravenous immunoglobulin in patients with Kawasaki disease.
Tse SM; Silverman ED; McCrindle BW; Yeung RS
J Pediatr; 2002 Apr; 140(4):450-5. PubMed ID: 12006960
[TBL] [Abstract][Full Text] [Related]
26. Initial intravenous immunoglobulin therapy without aspirin for acute Kawasaki disease: a retrospective cohort study with a Bayesian inference.
Hayashi K; Miyakoshi C; Hoshino S; Kobayashi N; Nakajima R; Sagawa H; Hayashiya T; Suzuki A; Aota C; Nishijima S; Shimizu Y; Yamakawa M; Tsuda E
BMJ Paediatr Open; 2024 Jan; 8(1):. PubMed ID: 38233084
[TBL] [Abstract][Full Text] [Related]
27. [Efficacy and safety of glucocorticoids in addition to intravenous immunoglobulin in the initial treatment of Kawasaki disease: a meta-analysis of randomized trials].
Hu JW; Zhou ZS; Yang L; Zheng CN; Wang KD
Zhonghua Yi Xue Za Zhi; 2011 May; 91(18):1259-64. PubMed ID: 21756798
[TBL] [Abstract][Full Text] [Related]
28. Re-treatment for immune globulin-resistant Kawasaki disease: a comparative study of additional immune globulin and steroid pulse therapy.
Hashino K; Ishii M; Iemura M; Akagi T; Kato H
Pediatr Int; 2001 Jun; 43(3):211-7. PubMed ID: 11380911
[TBL] [Abstract][Full Text] [Related]
29. Safety and efficacy of warfarin plus aspirin combination therapy for giant coronary artery aneurysm secondary to Kawasaki disease: a meta-analysis.
Su D; Wang K; Qin S; Pang Y
Cardiology; 2014; 129(1):55-64. PubMed ID: 25116427
[TBL] [Abstract][Full Text] [Related]
30. School-aged children with Kawasaki disease: high incidence of cervical lymphadenopathy and coronary artery involvement.
Fan PC; Chiu CH; Yen MH; Huang YC; Li CC; Lin TY
J Paediatr Child Health; 2003; 39(1):55-7. PubMed ID: 12542814
[TBL] [Abstract][Full Text] [Related]
31. Economic evaluation of intravenous immune globulin therapy for Kawasaki syndrome.
Klassen TP; Rowe PC; Gafni A
J Pediatr; 1993 Apr; 122(4):538-42. PubMed ID: 8463897
[TBL] [Abstract][Full Text] [Related]
32. Reevaluation of the efficacy of intravenous gammaglobulin in the prevention and treatment of coronary artery lesion in Kawasaki disease.
Qin L; Saumu MT; Wang H; Shi H; Hu X; Cheng P
J Huazhong Univ Sci Technolog Med Sci; 2005; 25(3):348-50, 370. PubMed ID: 16201293
[TBL] [Abstract][Full Text] [Related]
33. Predictors of intravenous immunoglobulin-resistant Kawasaki disease in children: a meta-analysis of 4442 cases.
Li X; Chen Y; Tang Y; Ding Y; Xu Q; Sun L; Qian W; Qian G; Qin L; Lv H
Eur J Pediatr; 2018 Aug; 177(8):1279-1292. PubMed ID: 29948255
[TBL] [Abstract][Full Text] [Related]
34. Revisiting the role of steroids and aspirin in the management of acute Kawasaki disease.
Dhanrajani A; Yeung RSM
Curr Opin Rheumatol; 2017 Sep; 29(5):547-552. PubMed ID: 28661936
[TBL] [Abstract][Full Text] [Related]
35. Efficacy of primary treatment with immunoglobulin plus ciclosporin for prevention of coronary artery abnormalities in patients with Kawasaki disease predicted to be at increased risk of non-response to intravenous immunoglobulin (KAICA): a randomised controlled, open-label, blinded-endpoints, phase 3 trial.
Hamada H; Suzuki H; Onouchi Y; Ebata R; Terai M; Fuse S; Okajima Y; Kurotobi S; Hirai K; Soga T; Ishiguchi Y; Okuma Y; Takada N; Yanai M; Sato J; Nakayashiro M; Ayusawa M; Yamamoto E; Nomura Y; Hashimura Y; Ouchi K; Masuda H; Takatsuki S; Hirono K; Ariga T; Higaki T; Otsuki A; Terauchi M; Aoyagi R; Sato T; Fujii Y; Fujiwara T; Hanaoka H; Hata A;
Lancet; 2019 Mar; 393(10176):1128-1137. PubMed ID: 30853151
[TBL] [Abstract][Full Text] [Related]
36. Efficacy of immunoglobulin plus prednisolone for prevention of coronary artery abnormalities in severe Kawasaki disease (RAISE study): a randomised, open-label, blinded-endpoints trial.
Kobayashi T; Saji T; Otani T; Takeuchi K; Nakamura T; Arakawa H; Kato T; Hara T; Hamaoka K; Ogawa S; Miura M; Nomura Y; Fuse S; Ichida F; Seki M; Fukazawa R; Ogawa C; Furuno K; Tokunaga H; Takatsuki S; Hara S; Morikawa A;
Lancet; 2012 Apr; 379(9826):1613-20. PubMed ID: 22405251
[TBL] [Abstract][Full Text] [Related]
37. Timing of intravenous immunoglobulin treatment and risk of coronary artery abnormalities in children with Kawasaki disease.
Bal AK; Prasad D; Umali Pamintuan MA; Mammen-Prasad E; Petrova A
Pediatr Neonatol; 2014 Oct; 55(5):387-92. PubMed ID: 24636168
[TBL] [Abstract][Full Text] [Related]
38. Management of acute and refractory Kawasaki disease.
Tacke CE; Burgner D; Kuipers IM; Kuijpers TW
Expert Rev Anti Infect Ther; 2012 Oct; 10(10):1203-15. PubMed ID: 23199405
[TBL] [Abstract][Full Text] [Related]
39. Intravenous gamma-globulin treatment and retreatment in Kawasaki disease. US/Canadian Kawasaki Syndrome Study Group.
Burns JC; Capparelli EV; Brown JA; Newburger JW; Glode MP
Pediatr Infect Dis J; 1998 Dec; 17(12):1144-8. PubMed ID: 9877364
[TBL] [Abstract][Full Text] [Related]
40. Treatment of Kawasaki disease with a moderate dose (1 g/kg) of intravenous immunoglobulin.
Khowsathit P; Hong-Hgam C; Khositseth A; Wanitkun S
J Med Assoc Thai; 2002 Nov; 85 Suppl 4():S1121-6. PubMed ID: 12549785
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
